ライフサイエンスコーパス: risperidone

1 ibitor bupropion and the dopamine antagonist risperidone.

2 luoxetine combination (OFC), quetiapine, and risperidone.

3 DTI data before and after a 6-week trial of risperidone.

4 e observed for aripiprazole, olanzapine, and risperidone.

5 e observed for aripiprazole, olanzapine, and risperidone.

6 piprazole, and parent training combined with risperidone.

7 lanzapine, 0.33 for quetiapine, and 0.32 for risperidone.

8 apine, 506 mg for quetiapine, and 2.4 mg for risperidone.

9 ODDI indices after short-term treatment with risperidone.

10 lanzapine, 0.34 for quetiapine, and 0.22 for risperidone.

11 215) for quetiapine, and 2.4 mg (SD=1.0) for risperidone.

12 on, particularly the atypical antipsychotic, risperidone.

13 lanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.

14 s compared with those receiving inositol and risperidone.

15 augmentation with lamotrigine, inositol, and risperidone.

16 .5-25.3) versus 26.7 (95% CI=25.2-28.2) with risperidone.

17 orms of the h5-HT7 receptor exposed to 20 nM risperidone.

18 lozapine than for olanzapine, quetiapine, or risperidone.

19 iprazine and 131 (57%) patients treated with risperidone.

20 ponse after 3 weeks received open adjunctive risperidone.

21 SD 0.6) for cariprazine and 3.8 mg (0.4) for risperidone.

22 curred in all patients but was resolved with risperidone.

23 e, total cholesterol, and triglycerides than risperidone.

24 than clozapine, haloperidol, olanzapine, and risperidone.

25 e long-acting injectable risperidone or oral risperidone.

26 rtality risk for olanzapine, quetiapine, and risperidone.

27 ipiprazole and 13 patients were treated with risperidone.

28 uring 7-day bupropion (0.32-1.8 mg/kg/h) and risperidone (0.001-0.0056 mg/kg/h) treatment periods.

29 e effects of the atypical antipsychotic drug risperidone (0.1 mg/kg) on DA, but not ACh, efflux in th

30 -20 mg/day), quetiapine (100-800 mg/day), or risperidone (0.5-4 mg/day) administered in twice-daily d

31 -20 mg/day), quetiapine (100-800 mg/day), or risperidone (0.5-4 mg/day).

32 ment with either olanzapine (2.5-20 mg/day), risperidone (0.5-6 mg/day), or molindone (10-140 mg/day,

33 2), ziprasidone (-0.25, -0.48 to -0.01), and risperidone (-0.14, -0.27 to -0.01) were significantly m

34 /kg vehicle) or three sham groups (4.5 mg/kg risperidone, 0.5 mg/kg haloperidol, or 1 mL/kg vehicle).

35 roups (0.045 mg/kg, 0.45 mg/kg, or 4.5 mg/kg risperidone; 0.5 mg/kg haloperidol; or 1 mL/kg vehicle)

36 treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).

37 eek of treatment with the antipsychotic drug risperidone (1-week post-treatment).

38 SB-399885 potentiated risperidone (1.0 mg/kg)-induced DA efflux in both region

39 usted mortality risk was increased with both risperidone (1.7%; 95% CI, 0.6%-2.8%; P = .003) and olan

40 , patients were randomly assigned to receive risperidone, 1 mg/d, or placebo for 6 weeks.

41 olanzapine=144, placebo=75, quetiapine=125, risperidone=124, UC=30 and ziprasidone=32), 4 of which w

42 , 40 or 80 mg twice daily (BID), placebo, or risperidone, 2 mg BID, for up to 6 weeks.

43 g, 4.5 mg [target dose], or 6 mg per day) or risperidone (3 mg, 4 mg [target dose], or 6 mg per day);

44 th an NNH of 26 (95% CI, 15-99); followed by risperidone, 3.7% (95% CI, 2.2%-5.3%; P < .01) with an N

45 eficits reoccurred after daily treatments of risperidone (4.5 mg/kg) and haloperidol (p < .05).

46 onse rates (molindone: 50%; olanzapine: 34%; risperidone: 46%) or magnitude of symptom reduction.

47 o treatment (230 for cariprazine and 231 for risperidone); 460 were included in the safety population

48 than in the group that continued to receive risperidone (48% [13 of 27 patients in group 2] vs. 15%

49 nts then received 16 weeks of treatment with risperidone, 51 FEP completed the trial.

50 n olanzapine (43.7%, 95% CI=28.8%-58.6%) and risperidone (54.3%, 95% CI=39.9%-68.7%).

51 for placebo, 79% from baseline; 7 [4-14] for risperidone, 58% from baseline; 6.5 [5-14] for haloperid

52 d 1.53 mg; quetiapine, 482 mg/day and 77 mg; risperidone, 6.3 mg/day and 1 mg; risperidone LAI, 36.6

53 ved placebo than in the groups that received risperidone (60% [24 of 40 patients in group 3] vs. 33%

54 PANSS-FSNS from baseline to week 26 than did risperidone (-8.90 points for cariprazine vs -7.44 point

55 5-HT(7)) receptor-inactivating properties of risperidone, 9-OH-risperidone, bromocriptine, methiothep

56 As in the recombinant cell line, risperidone, 9-OH-risperidone, methiothepin, and bromocr

57 idated for polymeric microspheres containing risperidone (a practically water insoluble small molecul

58 The atypical antipsychotic drug risperidone, a multireceptor antagonist, which lacks 5-H

59 Long-acting injectable risperidone, a second-generation antipsychotic agent, ma

60 The use of long-acting injectable risperidone after a first episode of schizophrenia has n

61 Olanzapine, quetiapine, and risperidone all produced significant improvements in neu

62 dition, treatment with the FDA-approved drug risperidone ameliorates the targeted repetitive behavior

63 Risperidone, amisulpride, and valproate did not influenc

64 pical, first-generation antipsychotic drug), risperidone (an atypical, second-generation antipsychoti

65 268 patients), 81% (111 of 137) who received risperidone and 87.8% (115 of 131) who received placebo

66 f elevation in plasma prolactin levels (with risperidone and 9-hydroxyrisperidone being exceptions),

67 comparing the long-acting injectable vs oral risperidone and cognitive remediation vs healthy-behavio

68 e acute administration of the combination of risperidone and DVX.

69 hat although single or multiple low doses of risperidone and haloperidol may be innocuous to subseque

70 everal marketed drugs (such as aripiprazole, risperidone and haloperidol).

71 Compositionally equivalent risperidone and LA formulations with variable burst rele

72 Risperidone and olanzapine did not demonstrate superior

73 The results show that both risperidone and olanzapine significantly improved perfor

74 Young adult male rats were treated with risperidone and paliperidone, atypical antipsychotic med

75 Adding EX/RP to SRIs was superior to both risperidone and pill placebo.

76 Adding EX/RP was also superior to risperidone and placebo in improving insight, functionin

77 Accordingly, Risperdal Consta(R) (Risperidone) and Lupron Depot(R) (Leuprolide acetate, LA

78 precursor (levodopa), a dopamine antagonist (risperidone), and a placebo (lactose) in three different

79 ptoms (NNH = 10 for olanzapine; NNH = 20 for risperidone), and urinary tract symptoms (NNH range = 16

80 core decrease >/=25%: 80% for EX/RP, 23% for risperidone, and 15% for placebo; P < .001).

81 for olanzapine, 2.46 (95% CI, 1.94-3.12) for risperidone, and 2.16 (95% CI, 1.88-2.48) for quetiapine

82 d to quetiapine, 29% of patients assigned to risperidone, and 21% of patients assigned to placebo (P=

83 (Y-BOCS score </=12: 43% for EX/RP, 13% for risperidone, and 5% for placebo; P = .001).

84 ved quetiapine, 18% of patients who received risperidone, and 5% of patients who received placebo dis

85 Aripiprazole, risperidone, and amisulpride increased P50 suppression i

86 ntadine, selegiline, olanzapine, quetiapine, risperidone, and citalopram do not appear to be effectiv

87 action of antipsychotic drugs, particularly risperidone, and further highlight the promise of optimi

88 ofiles of methylphenidate, aripiprazole, and risperidone, and of kinase drugs targeting the VEGF rece

89 ntipsychotic drugs, specifically quetiapine, risperidone, and olanzapine, are known to cause acute ki

90 ss akathisia than haloperidol, aripiprazole, risperidone, and olanzapine, but, again, evidence was ve

91 ole, chlorpromazine, quetiapine, olanzapine, risperidone, and ziprasidone all potently antagonize the

92 blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just di

93 Quetiapine, risperidone, and ziprasidone use were not associated wit

94 eridone, lurasidone, olanzapine, quetiapine, risperidone, and ziprasidone.

95 th different solubility profiles compared to risperidone; and 2) to determine whether release charact

96 l, these negative results with bupropion and risperidone are concordant with previous human laborator

97 (eg, clozapine, olanzapine, quetiapine, and risperidone) are associated with an increased risk of we

98 bility that highly prescribed drugs, such as risperidone, are irreversibly antagonizing GPCR function

99 icantly improved with long-acting injectable risperidone as compared with control treatments.

100 ratios were all more than 0.5 and they took risperidone at 3-6 mg/day for at least a month before pa

101 (+/-SE) HRSD-17 scores improved more in the risperidone augmentation group than in the placebo group

102 Risperidone augmentation produced a statistically signif

103 zide), leukaemia (alvocidib), schizophrenia (risperidone, belaperidone), malaria (mefloquine) and nic

104 Long-acting injectable risperidone better controlled mean levels of hallucinati

105 inactivating properties of risperidone, 9-OH-risperidone, bromocriptine, methiothepin, metergoline, a

106 than in patients treated with quetiapine or risperidone but not olanzapine.

107 ce were cataleptic following haloperidol and risperidone, but did not respond to clozapine's locomoto

108 In sum, we confirm that haloperidol and risperidone caused catalepsy in rodents, driven by stron

109 Risperidone caused greater in vitro block of the alterna

110 her risk of relapse after discontinuation of risperidone compared with continued risperidone treatmen

111 (N=52) showed a better treatment response to risperidone compared with other drugs, but this associat

112 ed improvement in symptoms when treated with risperidone compared with patients with fast metabolizer

113 I-resistant symptoms, 6-month treatment with risperidone compared with placebo did not reduce PTSD sy

114 -sensitive eticlopride and Na(+)-insensitive risperidone correspond to different degrees of inverse a

115 scribed in complex with the inverse agonists risperidone (D(2)R(ris)) and haloperidol (D(2)R(hal)).

116 Olanzapine, quetiapine, and risperidone demonstrated comparable effectiveness in ear

117 Treatment response to risperidone did not appear to depend upon these patient

118 Adherence to oral risperidone did not appear to differ before randomizatio

119 Risperidone did not reduce symptoms of depression (MADRS

120 Patients receiving risperidone did not significantly differ from those rece

121 Risperidone displays a novel mechanism of antagonism of

122 r quetiapine (dose range: 200-800 mg/day) or risperidone (dose range: 2-8 mg/day) for an 8-week perio

123 hours (42%), and weight gain (40%); and for risperidone, drowsiness (50%), menstrual irregularities

124 ion to 25 to 50 mg of long-acting injectable risperidone every two weeks or to a psychiatrist's choic

125 ed to harm [NNH] = 87), stroke (NNH = 53 for risperidone), extrapyramidal symptoms (NNH = 10 for olan

126 Pretreatment of the cells with 5 or 20 nM risperidone, followed by removal of the drug from the me

127 ith aripiprazole, olanzapine, quetiapine, or risperidone for 12 weeks.

128 ntinue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo f

129 ntinue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo f

130 of agitation or psychosis were treated with risperidone for 16 weeks, after which patients who respo

131 of agitation or psychosis were treated with risperidone for 16 weeks, after which patients who respo

132 ggression received open-label treatment with risperidone for 16 weeks.

133 d (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16

134 d (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16

135 te, patients with FEP were treated with oral risperidone for 4 weeks at an initial dose of 1 mg/day t

136 Olanzapine was superior to haloperidol and risperidone for reduction of negative symptoms.

137 ive treatment with lamotrigine, inositol, or risperidone for up to 16 weeks.

138 apine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously b

139 rpromazine, haloperidol, trifluoperazine, or risperidone) for 12 months or to switch their medication

140 roup (40.9%, 95% CI=16.8%-65.0%) than in the risperidone group (18.9%, 95% CI=0%-39.2%) had subsequen

141 t 52 weeks or withdrawal from study) and the risperidone group (at 12 weeks).

142 on in the oral group than in the long-acting risperidone group (chi21 = 6.1; P = .01).

143 r relapse rate was lower for the long-acting risperidone group compared with the oral group (5% vs 33

144 omization but was better for the long-acting risperidone group compared with the oral group (t80 = 5.

145 One patient in the risperidone group died of a cause regarded as unrelated

146 CAPS scores from baseline to 24 weeks in the risperidone group was -16.3 (95% CI, -19.7 to -12.9) and

147 e group and 229 (99%) of 230 patients in the risperidone group were included in the modified intentio

148 used treatment in the long-acting injectable risperidone group.

149 erphenazine group than in the olanzapine and risperidone groups.

150 Moreover, risperidone had differential effects than the brain on p

151 Molindone was superior to risperidone, haloperidol, and olanzapine in terms of wei

152 l antipsychotic drugs, such as clozapine and risperidone, have a high affinity for the serotonin 5-HT

153 , 95% confidence interval (CI): 1.22, 2.19), risperidone (HR = 1.60, 95% CI: 1.19, 2.14), or quetiapi

154 otics (HR = 2.89 [95% CI = 1.64-5.10]) or to risperidone (HR = 2.20 [95% CI = 1.14-4.26]).

155 lamotrigine may be superior to inositol and risperidone in improving treatment-resistant bipolar dep

156 uation rates) of olanzapine, quetiapine, and risperidone in patients early in the course of psychotic

157 ine in terms of weight gain, and superior to risperidone in terms of increase in prolactin release.

158 published showing effectiveness of low-dose risperidone in the management of behaviour problems as c

159 As in the recombinant cell line, exposure of risperidone-inactivated astrocyte r5-HT receptors to com

160 ITI-007 (60 mg and 120 mg), placebo, and risperidone, included for assay sensitivity, were evalua

161 bute to the potentiation of haloperidol- and risperidone-induced DA efflux in the mPFC or HIP.

162 As compared with a reference group of risperidone initiators, the risk was higher among those

163 cologic agents (dexamethasone, rivastigmine, risperidone, ketamine, dexmedetomidine, propofol, and cl

164 peridone, risperidone long-acting injection (risperidone LAI), and ziprasidone--were used to identify

165 and 77 mg; risperidone, 6.3 mg/day and 1 mg; risperidone LAI, 36.6 mg every 2 weeks and 0.42 mg; sert

166 0 points for cariprazine vs -7.44 points for risperidone; least squares mean difference -1.46, 95% CI

167 ce and music-related motivational responses, risperidone led to a reduction of both.

168 We demonstrate that levodopa and risperidone led to opposite effects in measures of music

169 A critical difference between naltrexone and risperidone loaded microspheres is their respective bi-p

170 pine, paliperidone, quetiapine, risperidone, risperidone long-acting injection (risperidone LAI), and

171 roate, olanzapine, paliperidone, quetiapine, risperidone long-acting injection, valproate, and placeb

172 ogical treatment (valproic acid, fluoxetine, risperidone, lorazepam).

173 A total of 180 patients received open-label risperidone (mean dose, 0.97 mg daily).

174 y), quetiapine (mean dose, 56.5 mg per day), risperidone (mean dose, 1.0 mg per day), or placebo.

175 lowed by haloperidol (mean=65.5%, SD=40.3%), risperidone (mean=49.2%, SD=33.9%), and quetiapine (mean

176 OCS scores based on mixed-effects models (vs risperidone: mean [SE], -9.72 [1.38]; P < .001 vs placeb

177 wed no significant difference in CAPS score (risperidone: mean, 64.43; 95% CI, 61.98 to 66.89, vs pla

178 nuation was longer for patients treated with risperidone (median: 7.0 months) and olanzapine (6.3 mon

179 months) than for quetiapine (median=3.3), or risperidone (median=2.8), but not for olanzapine (median

180 the recombinant cell line, risperidone, 9-OH-risperidone, methiothepin, and bromocriptine were found

181 In vivo pharmacokinetic profiles of the risperidone microsphere formulations following intramusc

182 validated for the compositionally equivalent risperidone microspheres based on the in vitro release d

183 njection) burst release were similar for the risperidone microspheres but were significantly differen

184 In vitro release of the risperidone microspheres was investigated using differen

185 g processes were investigated to produce the risperidone microspheres with similar drug loading (appr

186 t Risperdal(R) Consta(R) was used to prepare risperidone microspheres.

187 suggest that the apparent adverse effect of risperidone might result from treatment-related changes

188 n this study to explore the effect of 8-week risperidone monotherapy on NAA.

189 ith schizophrenia treated with quetiapine or risperidone monotherapy were randomized to 12 weeks of p

190 (FESP) at baseline and then after 8-weeks of risperidone monotherapy, and compared the findings to 38

191 36), by 5.3 kg (95% CI, 4.8 to 5.9 kg) with risperidone (n = 135), and by 4.4 kg (95% CI, 3.7 to 5.2

192 tients treated with cariprazine (n = 227) or risperidone (n = 229) in a clinical study evaluating neg

193 h olanzapine (N=133), quetiapine (N=134), or risperidone (N=133).

194 seline antipsychotic was olanzapine (N=319), risperidone (N=271), or quetiapine (N=94), the authors e

195 ived either single doses of aripiprazole and risperidone (n=28), amisulpride and lorazepam (n=30), or

196 ere randomly assigned to haloperidol (n=28), risperidone (n=29), or placebo (n=29).

197 gned to treatment with olanzapine (N=314) or risperidone (N=321), the authors assessed the impact of

198 al (olanzapine [N=19], quetiapine [N=15], or risperidone [N=16]).

199 163 who were eligible, 100 were randomized (risperidone, n = 40; EX/RP, n = 40; and placebo, n = 20)

200 Compared with risperidone, newer antipsychotics were not associated wi

201 In addition, risperidone occupies a sub-pocket near the Na(+) binding

202 antipsychotic drugs (APDs), e.g. clozapine, risperidone, olanzapine and ziprasidone, to improve cogn

203 ition of 5-HT(2A) by antipsychotics, such as risperidone, olanzapine or chlorpromazine prevented it.

204 icipated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol.

205 paring an atypical antipsychotic medication (risperidone, olanzapine, quetiapine, aripiprazole, zipra

206 outpatient treatment with an antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) or

207 l antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer's di

208 e the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with

209 le (BPRS) hostile suspiciousness factor, and risperidone on the BPRS psychosis factor.

210 Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS)

211 the Neuropsychiatric Inventory total score, risperidone on the Clinical Global Impression of Changes

212 howed greater improvement with olanzapine or risperidone on the Neuropsychiatric Inventory total scor

213 Patients were treated with oral risperidone (open label) for 4 weeks with dosages that w

214 gain after 12 weeks of treatment with either risperidone or aripiprazole in a double-blind randomized

215 and after 12 weeks of treatment with either risperidone or aripiprazole.

216 DG in the same animal, paliperidone, but not risperidone or fluoxetine (0.6 mg/kg/day) resulted in in

217 Adult rats were given either risperidone or olanzapine in their drinking water for 21

218 randomized to receive long-acting injectable risperidone or oral risperidone.

219 medicated patients with schizophrenia taking risperidone or paliperidone by regular intramuscular inj

220 e (OR, 1.53, 95% CI, 1.17-2.0; NNT, 10), and risperidone (OR, 1.83, 95% CI, 1.16-2.88; NNT, 8).

221 uetiapine (OR, 1.79; 95% CI, 1.33-2.42), and risperidone (OR, 2.37; 95% CI, 1.31-4.30).

222 -dose treatment with olanzapine, quetiapine, risperidone, or placebo for up to 36 weeks.

223 atment with olanzapine, quetiapine fumarate, risperidone, or placebo with the option of double-blind

224 asked, flexible-dose olanzapine, quetiapine, risperidone, or placebo.

225 eceive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone for up to 18 months.

226 inued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the tria

227 d-generation drugs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 m

228 I-007 60 mg (p = .017, effect size = .4) and risperidone (p = .013, effect size = .4) demonstrated an

229 001), 0.18 for quetiapine (P<.001), 0.26 for risperidone (P<.001), and 0.12 for ziprasidone (P<.06),

230 compared with 10 of 26 (38.5%) who continued risperidone (p<0.02).

231 5, or 50 mg) added to ongoing treatment with risperidone, paliperidone, or aripiprazole.

232 ion of the combination of DVX, 50 mg/kg, and risperidone, produced significantly greater increases in

233 67 patients who initiated use of olanzapine, risperidone, quetiapine, or haloperidol in 1999-2001 aft

234 More risperidone recipients than placebo recipients experienc

235 Headache (8.8% of risperidone recipients vs. 14.5% of placebo recipients),

236 fidence interval [CI]=1.38-1.73) followed by risperidone (reference), olanzapine (relative risk=0.99,

237 cinations, 13 of 17 (76.5%) who discontinued risperidone relapsed, compared with 10 of 26 (38.5%) who

238 Patients who received long-acting injectable risperidone reported more adverse events at the injectio

239 in the risk for malformations observed with risperidone requires additional study.

240 ses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride

241 %, and 71.4% for olanzapine, quetiapine, and risperidone, respectively.

242 Then, risperidone restored plasticity and reduced oxidative/ni

243 hort-term treatment with both quetiapine and risperidone resulted in improvements in social competenc

244 Ps: chlorpromazine (CLP), haloperidol (HAL), risperidone (RIS) and clozapine (CLZ), at concentrations

245 idone, olanzapine, paliperidone, quetiapine, risperidone, risperidone long-acting injection (risperid

246 ngle trial-based superiority, and except for risperidone's superiority at 3 and 6 months when requiri

247 Olanzapine and risperidone showed declining rates and quetiapine showed

248 antipsychotics (olanzapine, quetiapine, and risperidone) showed a dose-response increase in mortalit

249 2 from the helical conformation in the D(2)R/risperidone structure to an extended conformation simila

250 de structure but incompatible with the D(2)R/risperidone structure.

251 stration of the antipsychotics clozapine and risperidone suggesting that the loss of the kinase may d

252 patients who received long-acting injectable risperidone than among those who received oral antipsych

253 (RR, 1.26; 95% CI, 0.88-1.81) was found for risperidone that was independent of measured confounders

254 ight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative

255 risperidone therapy for 32 weeks (group 1), risperidone therapy for 16 weeks followed by placebo for

256 fashion, to one of three regimens: continued risperidone therapy for 32 weeks (group 1), risperidone

257 psychosis or agitation that had responded to risperidone therapy for 4 to 8 months, discontinuation o

258 Those who had a response to risperidone therapy were then randomly assigned, in a do

259 hotic use (i.e., olanzapine, quetiapine, and risperidone) throughout the 36-week trial, using logisti

260 of switching from olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate metabolic risk

261 s higher in the group that was switched from risperidone to placebo than in the group that continued

262 n the first of two studies, paliperidone and risperidone treatment (at 1mg/kg/day) resulted in increa

263 After 6 weeks of risperidone treatment and significant clinical improveme

264 Risperidone treatment exacerbated these deficits, perhap

265 Furthermore, risperidone treatment had a neurotrophic effect on the P

266 d their modulation by atypical antipsychotic risperidone treatment in rats with neonatal ventral hipp

267 However, fluoxetine, but not paliperidone or risperidone treatment increased BrdU positive cells in t

268 Risperidone treatment increased methamphetamine choice,

269 This is the first evidence that short-term risperidone treatment induces an acute reduction of MPFC

270 antipsychotic-naive SCZ patients with 8-week risperidone treatment to evaluate the association betwee

271 ight gain particularly being associated with risperidone treatment.

272 ation of risperidone compared with continued risperidone treatment.

273 With risperidone, triglycerides increased significantly (mean

274 Risperidone (up to 4 mg once daily) or placebo.

275 ere randomized to the addition of 8 weeks of risperidone (up to 4 mg/d), EX/RP (17 sessions delivered

276 ic (haloperidol, olanzapine, quetiapine, and risperidone), valproic acid and its derivatives, or an a

277 Adverse events were more common with risperidone vs placebo, including self-reported weight g

278 IP, but not the mPFC, DA efflux by 0.3 mg/kg risperidone was also potentiated by SB-399885, 3 mg/kg.

279 For obsessive-compulsive disorder, risperidone was associated with a 3.9-fold greater likel

280 As reported previously, discontinuation of risperidone was associated with a two- to fourfold incre

281 herapy for 4 to 8 months, discontinuation of risperidone was associated with an increased risk of rel

282 eatment of generalized anxiety disorder, and risperidone was associated with benefits in the treatmen

283 Risperidone was chosen as a model therapeutic and poly(l

284 After 4 weeks, the dosage of risperidone was increased to 2 mg/d in some cases.

285 The need for adjunctive risperidone was low and similar between groups (17% and

286 fective than quetiapine and ziprasidone, and risperidone was more effective than quetiapine.

287 and sertindole (-0.40; -0.74 to -0.04); and risperidone was more effective than sertindole (-0.32; -

288 Long-acting injectable risperidone was not superior to a psychiatrist's choice

289 f superiority for olanzapine, clozapine, and risperidone was seen in other efficacy outcomes, but res

290 whereas the recovery rates with inositol and risperidone were 17.4% and 4.6%, respectively.

291 ice treated with haloperidol, clozapine, and risperidone were assessed for locomotor activity and cat

292 Olanzapine and risperidone were associated with significantly greater w

293 Clinical outcomes with risperidone were equal to those with olanzapine, and res

294 han 0.5 and were stabilized on 3-6 mg/day of risperidone were randomly assigned to receive placebo (N

295 eatment dosage of olanzapine, quetiapine, or risperidone were randomly assigned to switch to ari-pipr

296 ted with good response to a 6-week course of risperidone, whereas pre-treatment VTA/midbrain connecti

297 benefit or a very small benefit, except for risperidone, which had a small-to-moderate effect on qua

298 administration of haloperidol and high-dose risperidone, which was most likely secondary to the seve

299 ividuals randomly assigned to olanzapine and risperidone who were continuing with their baseline medi

300 previously unavailable biomarker to indicate risperidone with a similar pharmacological mechanism, al

301 nd-generation antipsychotics (olanzapine and risperidone) with a first-generation antipsychotic (moli